Human Pathology
Volume 41, Issue 2 , Pages 255-261 , February 2010

Progressive loss of selenium-binding protein 1 expression correlates with increasing epithelial proliferation and papillary complexity in ovarian serous borderline tumor and low-grade serous carcinoma

Received 23 April 2009 ,Revised 23 July 2009 ,Accepted 30 July 2009.

References 

  1. Seidman JD, Soslow RA, Vang R, et al. Borderline ovarian tumors: diverse contemporary viewpoints on terminology and diagnostic criteria with illustrative images. Hum Pathol. 2004;35:918–933
  2. Shih IM, Kurman RJ. Ovarian tumorigenesis: a proposed model based on morphological and molecular genetic analysis. Am J Pathol. 2004;164:1511–1518
  3. Shih IM, Kurman RJ. Molecular pathogenesis of ovarian borderline tumors: new insights and old challenges. Hum Cancer Res. 2005;11:7273–7279
  4. Huang KC, Park DC, Ng SK, et al. Selenium binding protein 1 in ovarian cancer. Int J Cancer. 2006;118:2433–2440
  5. Clark LC, Combs GF, Turnbull BW, et al. Effects of selenium supplementation for cancer prevention in patients with carcinoma of the skin. A randomized controlled trial. Nutritional Prevention of Cancer Study Group. JAMA. 1996;276:1957–1963
  6. Fleming J, Ghose A, Harrison PR. Molecular mechanisms of cancer prevention by selenium compounds. Nutr Cancer. 2001;40:42–49
  7. Rayman MP. The importance of selenium to human health. Lancet. 2000;356:233–241
  8. Yang M, Sytkowski AJ. Differential expression and androgen regulation of the human selenium-binding protein gene hSP56 in prostate cancer cells. Cancer Res. 1998;58:3150–3153
  9. Chen G, Wang H, Miller CT, et al. Reduced selenium-binding protein 1 expression is associated with poor outcome in lung adenocarcinomas. J Pathol. 2004;202:321–329
  10. Kim H, Kang HJ, You KT, et al. Suppression of human selenium-binding protein 1 is a late event in colorectal carcinogenesis and is associated with poor survival. Proteomics. 2006;6:3466–3476
  11. Stammer K, Edassery SL, Barua A, et al. Selenium-binding protein 1 expression in ovaries and ovarian tumors in the laying hen, a spontaneous model of human ovarian cancer. Gynecol Oncol. 2008;109:115–121
  12. Silverberg SG, Bell DA, Kurman RJ, et al. Borderline ovarian tumors: key points and workshop summary. Hum Pathol. 2004;35:920–927
  13. Bansal MP, Mukhopadhyay T, Scott J, Cook RG, Mukhopadhyay R, Medina D. DNA sequencing of a mouse liver protein that binds selenium: implications for selenium's mechanism of action in cancer prevention. Carcinogenesis. 1990;11:2071–2073
  14. Ho CL, Kurman RJ, Dehari R, Wang TL, Shih IM. Mutations of BRAF and KRAS precede the development of ovarian serous borderline tumors. Cancer Res. 2004;64:6915–6918
  15. Combs GF, Gray WP. Chemopreventive agents: selenium. Pharmacol Ther. 1998;79:179–192
  16. Ip C. Lessons from basic research in selenium and cancer prevention. J Nutr. 1998;128:1845–1854
  17. Medina D. Mechanisms of selenium inhibition of tumorigenesis. Adv Exp Med Biol. 1986;206:465–472

PII: S0046-8177(09)00283-4

doi: 10.1016/j.humpath.2009.07.019

Human Pathology
Volume 41, Issue 2 , Pages 255-261 , February 2010

Article Tools

* Image Usage & Resolution